. Author manuscript; available in PMC: 2009 Jul 1.

Published in final edited form as: Nat Rev Drug Discov. 2008 Jun 20;7(7):568–574. doi: 10.1038/nrd2520

Table 1.

Examples of recently approved or emerging pharmacogenetic tests

Gene	Drug	Consequence
KIT mutations^*	Imatinib mesylate^‡	Altered survival
TPMT	Mercaptopurine and azathioprine^*	Neutropaenia
UGT1A1^*	Irinotecan^‡	Neutropaenia
CYP2C9/VKORC1	Warfarin	International normalized ratio
CYP2D6^*	5-HT₃ receptor antagonists	Inadequate anti-emetic control
	Antidepressants	Inadequate benefit
	ADHD drugs	Inadequate benefit
	Codeine derivatives^*	Inadequate benefit

US Food and Drug Administration (FDA)-approved device.

^‡

FDA package insert information. 5-HT₃, 5-hydroxytryptamine (serotonin) 3; ADHD, attention-deficit/hyperactivity disorder; CYP, cytochrome P450; TPMT, thiopurine S-methyltransferase; UGT1A1, UDP glucuronosyltransferase 1 family, polypeptide A1; VKORC1, vitamin K epoxide reductase complex, subunit 1.